For the initiated, those who have read or listened to the org Valmiki #Ramayan, watching the movie is unnecessary & will surely draw strong criticism of subversion!
For the uninitiated, the clueless, it is the beginning of an initiation, of a narrative that is NOT #Ramayana!
Stopping GLP-1 treatment in people with diabetes.
Increased risks of heart attacks and strokes!
Need to have a real good reason to stop!
#endocrinology#diabetes#GLP1
Stopping GLP-1 treatment linked to twice the risk of heart attack, stroke or death compared with continuing, in people with type 2 diabetes and no cardiovascular disease, according to a new study.
Find out more in @LancetRH_Europe: https://t.co/iNJmDhOPAU
@PathoGuy Very rare but serious association
About 6.4/10,000 users (vs 3.8/10,000 in non users)
Diabetes and sleep apnea increase risk. Difficult to predict and no effective treatment .
Association only, causation not proven
Benefits of GLP outweigh risks in carefully chosen pts!
FDA update on #GLP1 safety communication
#NAION risk - a rare but potentially sight threatening complication
6:100,000 with risk factors including diabetes and OSA
#drug#glp1#obesity
Today, we are informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of GLP-1 RA medications.
NAION is a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss. Symptoms of NAION include sudden, painless vision loss in one eye that patients may notice upon waking: visual defects such as blind spots, distortion of colors, blurriness, or tunnel vision.
Patients should contact their health care professional right away if they have any of these symptoms. https://t.co/qeTuSSQUzS